Eko Low Ejection Fraction Tool (ELEFT) vs Lung Density Analysis

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Eko Low Ejection Fraction Tool (ELEFT)

by Eko Health

Lung Density Analysis

by IMBIO

AI Verdict

Tool A, Eko Low Ejection Fraction Tool, is designed for early heart failure detection using AI-powered digital stethoscopes during routine physical exams. In contrast, Tool B, Lung Density Analysis, provides quantitative analysis of lung conditions from CT scans for the diagnosis and management of diseases like COPD and emphysema. While both are FDA-cleared AI tools in the broader cardio-thoracic health space, their distinct input modalities (stethoscopes vs. CT scans) and primary clinical applications make them adjacent rather than direct competitors.

Choose Eko Low Ejection Fraction Tool (ELEFT) if…

Choose Eko Low Ejection Fraction Tool (ELEFT) if your primary goal is to non-invasively screen for early indicators of heart failure during routine physical examinations. This tool is ideal for clinicians seeking to quickly identify patients at risk of low ejection fraction using a digital stethoscope, enabling timely referrals and interventions.

View Eko Low Ejection Fraction Tool (ELEFT) →

Choose Lung Density Analysis if…

Choose IMBIO Lung Density Analysis if you require detailed quantitative analysis and 3D visualization of lung conditions from CT scans for the diagnosis and management of diseases like COPD and emphysema. This software is best suited for radiologists and pulmonologists needing automated, precise insights into lung density and structure to guide personalized patient care and monitor disease progression.

View Lung Density Analysis →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Eko Low Ejection Fraction Tool (ELEFT)	Lung Density Analysis
Pricing	Contact for pricing	Contact for pricing
Deployment	Cloud-based software integrated with Eko digital stethoscopes.	Cloud-based, Locally virtualized (VM, Docker), Integration in PACS, AI marketplace/distribution platforms, Stand-alone web-based.
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Eko Low Ejection Fraction Tool (ELEFT)

ELEFT integrates seamlessly into a routine physical exam using a familiar digital stethoscope, providing rapid results in approximately 15 seconds. This point-of-care integration makes it highly accessible and straightforward for clinicians. Lung Density Analysis, while automated, requires a CT scan, which is a more involved and less immediate process.

Clinical Value

Tie

Both tools are FDA-cleared and address significant clinical needs. ELEFT aids in the early, non-invasive detection of low ejection fraction, a key indicator of heart failure, during routine exams. Lung Density Analysis provides crucial quantitative analysis and 3D visualization from CT scans for the diagnosis and management of complex lung conditions like COPD and emphysema. Their value is high but in different clinical contexts.

Pricing & Value

Tie

Both Eko Low Ejection Fraction Tool and IMBIO's Lung Density Analysis require direct contact for pricing information, and neither publicly discloses specific costs or detailed value propositions. Without transparent pricing or comparative ROI data, it is impossible to determine which offers better value.

Enterprise Readiness

Lung Density Analysis

IMBIO's Lung Density Analysis offers superior deployment flexibility, supporting cloud-based, locally virtualized (VM, Docker), PACS integration, and availability on AI marketplaces. This broad range of options allows for greater adaptability to diverse enterprise IT infrastructures and workflows. ELEFT, while part of an enterprise platform, is primarily cloud-based with stethoscope integration.

Innovation

Eko Low Ejection Fraction Tool (ELEFT)

ELEFT demonstrates a more disruptive innovation by bringing AI-powered diagnostics for a critical condition (low ejection fraction) to the point of care during a routine physical exam via a digital stethoscope. This makes advanced screening highly accessible. While Lung Density Analysis offers sophisticated quantitative imaging, the application of AI to medical image analysis is a more established field.

Support & Docs

Tie

Both companies offer robust support and documentation. Eko provides a comprehensive Help Center for both individual and enterprise users, including user manuals, FAQs, and options to schedule support calls. IMBIO offers a dedicated support portal with contact options and provides detailed, versioned, and multi-language user manuals for its products. Both demonstrate strong commitment to user assistance.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Eko Low Ejection Fraction Tool (ELEFT)	Lung Density Analysis
Tool Name	Eko Low Ejection Fraction Tool (ELEFT)	Lung Density Analysis
Company	Eko Health	IMBIO
Primary Clinical Focus	Early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams.	Quantitative analysis and 3D visualization of lung conditions from CT scans, aiding in the diagnosis and management of diseases like COPD and emphysema.
Key Technology/Input	AI algorithm, integrates with Eko digital stethoscopes, analyzes ECG and heart sound recordings.	AI-driven medical imaging software, quantitative analysis and 3D visualization of lung conditions from CT scans.
Target Specialties	Cardiology, Family Medicine, Internal Medicine	Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring Eko Low Ejection Fraction Tool (ELEFT) and Lung Density Analysis.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into a physician's existing clinical workflow for patient assessment and diagnosis?

Eko Low Ejection Fraction Tool (ELEFT) integrates into routine physical exams, providing AI-powered low ejection fraction detection in approximately 15 seconds using an Eko digital stethoscope. This aids in early heart failure risk identification during a standard patient encounter. IMBIO's Lung Density Analysis integrates with CT scan workflows, providing automated quantitative analysis and 3D visualization of lung conditions directly to PACS, assisting in the diagnosis and management of diseases like COPD and emphysema.

For which specific medical specialties and patient conditions are these tools primarily designed?

ELEFT is primarily designed for Cardiology, Family Medicine, and Internal Medicine to aid in the early identification of low ejection fraction, a key indicator of heart failure, during routine physical exams. IMBIO's Lung Density Analysis is tailored for Pulmonology and Radiology, focusing on the diagnosis and management of lung conditions such as COPD, emphysema, asthma, and Bronchiolitis Obliterans Syndrome (BOS) using CT scans.

What type of patient data do these tools utilize, and how do their outputs integrate with existing EHR systems or imaging archives?

ELEFT analyzes ECG and heart sound recordings captured by Eko digital stethoscopes, providing results as part of the SENSORAu2122 platform with cloud-based data processing and storage. IMBIO's Lung Density Analysis processes CT scans, providing fully automated quantitative analysis and 3D visualizations that can be integrated directly into PACS and generate patient-centered reports.

What are the key performance claims or clinical utilities that demonstrate the accuracy and sensitivity of each tool?

ELEFT is an FDA-cleared AI algorithm that achieved a sensitivity of 74.7% and specificity of 77.5% for detecting LVEF <40% in a multi-site clinical study of 3,456 patients, aiding in early heart failure risk identification. IMBIO's Lung Density Analysis offers automated detection, visualization, and quantification of emphysema, validated for low-dose CT scans in lung cancer screening, and provides advanced density analysis for various lung conditions.

What is the expected learning curve for physicians to effectively utilize these tools, and how quickly can clinical value be realized?

ELEFT integrates with familiar Eko digital stethoscopes and provides results in approximately 15 seconds during a routine physical exam, suggesting a rapid learning curve and quick time-to-value for early heart failure risk identification. IMBIO's Lung Density Analysis offers automated workflows and detailed quantitative reports from CT scans, which implies that once integrated into the imaging workflow, it can provide immediate value through enhanced diagnostic insights and personalized patient care.

What are the considerations for deploying these tools across multiple clinical sites or a larger healthcare system?

ELEFT is part of Eko's SENSORAu2122 platform, an enterprise solution with cloud-based data processing and storage, suggesting it is designed for scalable deployment across multiple sites where Eko digital stethoscopes are used. IMBIO's Lung Density Analysis offers flexible deployment options including cloud-based, locally virtualized (VM, Docker), integration in PACS, and AI marketplace platforms, providing versatility for multi-site rollouts depending on the existing IT infrastructure.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Eko Low Ejection Fraction Tool (ELEFT) or Lung Density Analysis

Backers

Who funded each tool's parent company.